Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status

Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status by Biopsy and mRNA Profiles (TIMELY Study)

Status

Terminated

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00731874

Acronym

TIMELY

Enrollment

Registered

2008-08-11

Start date

2008-08-31

Completion date

2013-07-31

Last updated

2019-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunosuppression

Keywords

Kidney transplantation, Immunosuppression, Minimization, Tacrolimus, Prograf, Thymoglobulin

Brief summary

Tacrolimus (Prograf) is a medication that is commonly used in patients who receive a kidney transplant. It is considered to be one of the most important medications that prevent rejection of the transplant kidney by suppressing the immune system. Although tacrolimus is good at preventing rejection, it does have some unwanted side effects. These side effects include high blood pressure, increase in blood sugar, headache, and tremor. In addition, tacrolimus causes some damage to the transplant kidney over time, by causing healthy tissue to turn into scar tissue that does not function as well as healthy tissue. Therefore, kidney function may be reduced over time. In the first three months after kidney transplant, Prograf levels are kept between 8 to 10 ng/mL. This study will compare two groups of patients that will both have their tacrolimus dose reduced slowly over three months to prevent rejection while decreasing the risk of causing toxic effects to the kidney. One group will have their Prograf levels kept between 6 and 8 ng/mL, while the second group will have their levels kept between 3 and 5 ng/mL. We will then compare the two groups to see if there are any differences in their kidney function over time.

Detailed description

The objective of this study is to assess the safety and efficacy of an immunosuppression-minimizing regimen consisting initially of Thymoglobulin induction in combination with tacrolimus, mycophenolate mofetil, and rapid steroid withdrawal. The protocol will minimize long-term calcineurin inhibitor exposure and toxicity by weaning tacrolimus starting at 3 months after transplantation. Patients will be eligible to participate in this study only if they have already consented to participate in another study entitled The use of urinary PCR test to help detect rejection in kidney transplant patients. In The use of urinary PCR test to help detect rejection in kidney transplant patients, kidney allograft status (ie. whether or not there is any immunologic activity in the transplant kidney)is characterized with the use of protocol biopsies, diagnostic biopsies, and urinary PCR profiles. At 3 months after transplant, these patients are on an immunosuppression regimen consisting of tacrolimus (Prograf) and mycophenolate mofetil (CellCept). Prograf dosing is managed through the measurement of trough levels. For the first 3 months after transplant, patients are maintained at a trough level between 8 to 10 ng/ml. After 3 months, this target level is lowered in order to minimize long-term exposure to immunosuppressive agents. However, there is no consensus as to what the proper level should be after the first 3 months. Therefore, this study will randomize patients to 2 groups, one group will have their trough level targeted between 6 to 8 ng/mL while the other group will have their trough targeted between 3 and 5 ng/mL. By doing this study, we hope to determine which trough level is best, both for protecting the patient from rejection and protecting the patient from the adverse effects of the immunosuppressive medications. At New York Weill Cornell Center, we are in a unique position to attempt immunosuppression minimization due to our ability to non-invasively monitor patients using their urine. Previous investigations performed at this center have demonstrated the diagnostic accuracy of mRNA levels of cytotoxic attack molecules in urinary cells. Preliminary data has shown that during acute rejection, Granzyme B and Perforin are strongly expressed in the urine. The sensitivity of the uPCR test was 88% with a specificity of 79%. All kidney transplant recipients at our center are invited to participate in the research study entitled The use of urinary PCR test to help detect rejection in kidney transplant patients. In this protocol, serial analyses of urinary cells are performed to determine 1) if changes in mRNA levels will predict clinical acute rejection and 2) if these levels correlate with the presence of subclinical acute rejection. Kidney transplant recipients have serial urinary PCR measurements. In addition, patients undergo protocol biopsies of the transplant kidney at 3, 15, and 36 months after transplant. The biopsies help to show the correlation between the PCR results and the pathology of the kidney. It may also serve to detect rejection when the blood tests or urinary PCR do not show it. In a small subset of patients, urinary gene expression profile of cytotoxic attack molecules was able to predict acute rejection prior to clinical diagnosis by renal allograft biopsy. Because we have the ability to monitor our transplant recipients using the urinary PCR protocol, we can safely minimize tacrolimus exposure over time by monitoring patients non-invasively on a real-time basis. Minimization of immunosuppression over time in a kidney transplant recipient is important in order to prevent or minimize some of the leading causes of kidney graft loss (defined as return to dialysis). Although immunosuppressive medications are excellent at preventing rejection, they do have detrimental effects on the cardiovascular system as well as to the transplant kidney itself. One major cause of kidney graft loss today is chronic allograft nephropathy (CAN). Formerly known as chronic rejection, CAN has been described as the progressive decline in allograft function that occurs months or years after transplantation, and it is the second leading cause of kidney graft loss. Biopsies of kidney allografts with CAN may show inflammation, fibrosis, glomerulosclerosis, tubular atrophy, and vascular smooth muscle proliferation. The scarring and fibrosis associated with CAN is generally irreversible. A new goal within the modern transplant arena is to prevent CAN from occurring by: 1. decreasing early acute rejection episodes 2. decreasing calcineurin inhibitor-related nephrotoxicity With the use of modern immunosuppressive agents and induction therapy, we have already decreased early acute rejection episodes significantly. At this time, we now want to begin to study the potentially beneficial effects that calcineurin inhibitor withdrawal may have on kidney function as well as long-term graft survival.

Interventions

DRUGTacrolimus

Dosed to achieve target trough concentrations.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age \> 18 years * Renal allograft recipients who received a steroid-sparing immunosuppression protocol with rabbit anti-thymocyte globulin (Thymoglobulin) induction * Patient must have previously enrolled in protocol entitled The use of urinary PCR test to help detect rejection in kidney transplant patients * Recipients must agree to undergo all standard post-transplant protocol biopsies * Recipients must be at least 3 months post-transplant and the three most recent urinary profiles must demonstrate immunologic quiescence as determined by measurement of Granzyme B and Perforin copy numbers * Patient must provide informed consent to participate in the research study

Exclusion criteria

* Patient is a high-risk recipient (defined as peak or current PRA \>50% or a re-transplant recipient who lost prior graft within 1 year due to immunologic reasons) * Patients who require maintenance steroids for another medical condition (such as asthma) * Patients who are taking less than 1 gram/day of mycophenolate mofetil * Multiple organ transplant recipients (such as kidney-pancreas) * Patients with one or more acute rejection episodes within the first 3 months after transplant * Three-month protocol biopsy showing clinical acute rejection (BANFF grade 1a or higher) * Patient with documented or suspected non-compliance with transplant medications in the first 3 months after transplant

Design outcomes

Primary

Measure	Time frame
Number of Participants With Biopsy-confirmed Acute Rejection and/or Progression of Histologically Proven Chronic Allograft Nephropathy at 15 Months After Transplantation.	15 months post-transplant

Secondary

Measure	Time frame	Description
Graft Survival	36 months post-transplant	—
Change in Incidence and Severity of Interstitial Fibrosis/Tubular Atrophy (IF/TA) From the Baseline 3-month Biopsy to the 36-month Biopsy	36 months post-transplant	Compared to the baseline biopsy performed at the time of study entry at 3 months, was there new development (incidence) or progression (severity) of interstitial fibrosis/tubular atrophy (formerly called chronic allograft nephropathy) in the biopsy performed at 36 months.
Renal Function (Estimated Glomerular Filtration Rate)	36 months post-transplant	—
Development of Donor Specific Antibody (DSA)	36 months post-transplant	Percent of subjects who developed new donor specific antibody (mean fluorescence intensity \> 3,000) after enrollment, within 36 months of transplant
Patient Survival	36 months post-transplant	—
Severity of Acute Rejection (by Banff Criteria and Need for Anti-lymphocyte Agents to Treat Acute Rejection)	36 months post-transplant	The severity of acute rejection may be assessed by the Banff criteria. The Banff Classification of Allograft Pathology is an international consensus classification for the reporting of renal allograft biopsies, and provides critical information enabling the diagnosis and grading of pathologic changes, can help to predict response to treatment, and can help to determine the long-term prognosis of the organ. Anti-lymphocyte agents (specifically rabbit anti-thymocyte globulin) are used to treat more severe cases of acute rejection, and thus may serve as a surrogate marker of severity.
Incidence of Opportunistic Infection	36 months post-transplant	—
Development of New Onset Diabetes Mellitus	36 months post-transplant	—
Incidence of Acute Rejection	36 months post-transplant	Incidence of biopsy-proven acute rejection

Countries

United States

Participant flow

Pre-assignment details

34 subjects consented for the study; 11 were enrolled but not randomized due to the following: withdrew consent/refused transplant biopsy (n=4); donor specific antibody detected during screening (n=3); excluded by findings of kidney transplant biopsy (n=2); fluctuation in renal function (n=1); study terminated prior to randomization (n=1).

Participants by arm

Arm	Count
Arm 1 (Target Tacrolimus 6 to 8 ng/mL) Target tacrolimus trough concentration of 6 to 8 ng/mL Tacrolimus: Dosed to achieve target trough concentrations.	10
Arm 2 (Target Tacrolimus 3 to 5 ng/mL) Target tacrolimus trough concentration of 3 to 5 ng/mL Tacrolimus: Dosed to achieve target trough concentrations.	13
Total	23

Baseline characteristics

Characteristic	Arm 2 (Target Tacrolimus 3 to 5 ng/mL)	Arm 1 (Target Tacrolimus 6 to 8 ng/mL)	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	2 Participants	0 Participants	2 Participants
Age, Categorical Between 18 and 65 years	11 Participants	10 Participants	21 Participants
Age, Continuous	56.1 years STANDARD_DEVIATION 10.2	48.4 years STANDARD_DEVIATION 11.3	52.7 years STANDARD_DEVIATION 11.1
Region of Enrollment United States	13 participants	10 participants	23 participants
Sex: Female, Male Female	2 Participants	4 Participants	6 Participants
Sex: Female, Male Male	11 Participants	6 Participants	17 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk
deaths Total, all-cause mortality	— / —	— / —
other Total, other adverse events	3 / 10	7 / 13
serious Total, serious adverse events	0 / 10	0 / 13

Outcome results

Primary

Number of Participants With Biopsy-confirmed Acute Rejection and/or Progression of Histologically Proven Chronic Allograft Nephropathy at 15 Months After Transplantation.

Time frame: 15 months post-transplant

Arm	Measure	Value (NUMBER)
Arm 1 (Target Tacrolimus 6 to 8 ng/mL)	Number of Participants With Biopsy-confirmed Acute Rejection and/or Progression of Histologically Proven Chronic Allograft Nephropathy at 15 Months After Transplantation.	0 participants
Arm 2 (Target Tacrolimus 3 to 5 ng/mL)	Number of Participants With Biopsy-confirmed Acute Rejection and/or Progression of Histologically Proven Chronic Allograft Nephropathy at 15 Months After Transplantation.	1 participants

Secondary

Change in Incidence and Severity of Interstitial Fibrosis/Tubular Atrophy (IF/TA) From the Baseline 3-month Biopsy to the 36-month Biopsy

Compared to the baseline biopsy performed at the time of study entry at 3 months, was there new development (incidence) or progression (severity) of interstitial fibrosis/tubular atrophy (formerly called chronic allograft nephropathy) in the biopsy performed at 36 months.